Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies

Acta Neuropathologica

Volumn 111, Issue 2, 2006, Pages 101-108

  Klucken, Jochen ^a,b   Ingelsson, Martin ^a   Shin, Youngah ^a   Irizarry, Michael C ^a   Hedley Whyte, E T ^a   Frosch, Matthew P ^a   Growdon, John H ^a   McLean, Pamela J ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Synuclein; Heat shock proteins; Lewy body dementia

Indexed keywords

ALPHA SYNUCLEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; SYNAPTOPHYSIN; TRITON X 100;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NEOCORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SOLUBILITY; STEREOLOGY; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; DETERGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; LEWY BODY DISEASE; MALE; NEOCORTEX; OCTOXYNOL; SOLUBILITY; SYNAPTOPHYSIN; TEMPORAL LOBE;

EID: 33646197357     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-005-0027-7     Document Type: Article

References (37)

1. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868
2. Auluck PK, Meulener MC, Bonini NM (2005) Mechanisms of suppression of alpha-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280:2873-2878
3. Bonini NM (2002) Chaperoning brain degeneration. Proc Natl Acad Sci USA 99(Suppl 4):16407-16411
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134
5. Buldyrev SV, Cruz L, Gomez-Isla T, Gomez-Tortosa E, Havlin S, Le R, Stanley HE, Urbanc B, Hyman BT (2000) Description of microcolumnar ensembles in association cortex and their disruption in Alzheimer and Lewy body dementias. Proc Natl Acad Sci USA 97:5039-5043
6. Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, Masters CL, McLean CA (2000) Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol Dis 7:192-200
7. Cantuti-Castelvetri I, Klucken J, Ingelsson M, Ramasamy K, Keller-McGandy CE, McLean PJ, Frosch M, Hyman BT, Standaert DG (2005) Altered expression and solubility of alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 64:1058-1066
8. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
9. Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 74:852-856
10. Dalfo E, Albasanz JL, Martin M, Ferrer I (2004) Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/ phospholipase C (PLCbeta1) interactions. Brain Pathol 14:388-398
11. Dickson DW, Davies P, Mayeux R, Crystal H, Horoupian DS, Thompson A, Goldman JE (1987) Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. Acta Neuropathol (Berl) 75:8-15
12. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24:6715-6723
13. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59:1381-1389
14. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ (2000) Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 157:361-368
15. Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, Hyman BT (1999) Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 53:2003-2009
16. Gomez-Tortosa E, Irizarry MC, Gomez-Isla T, Hyman BT (2000) Clinical and neuropathological correlates of dementia with Lewy bodies. Ann NY Acad Sci 920:9-15
17. Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 105:341-350
18. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925-931
19. Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-2225
20. Klucken J, McLean P, Gomez-Tortosa E, Ingelsson M, Hyman B (2003) Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res 11:1683-1691
21. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 279:25497-25502
22. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P (2003) Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 106:83-88
23. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
24. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280:31664-31672
25. Lippa CF, Smith TW, Swearer JM (1994) Alzheimer's disease and Lewy body disease: A comparative clinicopathological study. Ann Neurol 35:81-88
26. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47:1113-24
27. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT (2002) TorsinA and heat shock proteins act as molecular chaperones: Suppression of alpha-synuclein aggregation. J Neurochem 83:846-854
28. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET (1999) Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 58:1147-1155
29. Perry R, McKeith I, Perry E (1997) Lewy body dementia - clinical, pathological and neurochemical interconnections. J Neural Transm Suppl 51:95-109
30. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
31. Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ (1999) Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Arch Neurol 56:1458-1461
32. Samuel W, Alford M, Hofstetter CR, Hansen L (1997) Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 56:499-508
33. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37:583-595
34. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841
35. de Vos RA, Jansen EN, Stam FC, Ravid R, Swaab DF (1995) 'Lewy body disease': Clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 97:13-22
36. White CLI, Welch EM, Brown DR, Speciale SG, Sontag E (1997) Production and characterization of a recombinant synaptophysin fragment suitable for use as a standard in immunoassays. J Neuropath Exp Neurol 56:608
37. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173